Australian Primary Hemp Ltd (APH)

APH Chart

vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Advanced

Show News Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day Mov Avgs 9-day 21-day 30-day 200-day Simple Exponential Weighted vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day 9/21 Cross 10/30 Cross Golden Cross Vol RSI BB

Day 3m 1yr 5yr 10yr

APH's Principal Activity is the produces, manufactures and distributes a range of hemp products under the Australian Primary Hemp brand, to retail, wholesale and white label customers in Australia. APH engages across the hemp value chain, encompassing hemp seed selection, farming, processing, packaging as well as distribution and sale of bulk and retail products.

Announcements

Company Overview

Dividend History

Directors & Management

Name	Title	Since	Bio
Mr Neale Joseph	Chief Executive Officer, Managing Director	Mar 2020	Mr Neale Joseph Chief Executive Officer, Managing Director Mr Joseph joined APH as Head of Product in January 2020. Neale has experience in FMCG, pharmacy, B2B distribution, procurement, and operations to the APH Board. In his previous CEO roles, Neale has led businesses across Australia, New Zealand, Asia Pacific, and the Middle East. Prior to joining APH, Neale co-founded a start-up in the natural health and beauty industry where he grew distribution to retailers in Australia, New Zealand, Canada, the United States, and Europe.
Mr James Hood	Executive Director, Chief Operating Officer	Oct 2019	Mr James Hood Executive Director, Chief Operating Officer Mr Hood have experience in production facility development and an network of farmers, which has positioned Australian Primary Hemp well to produce a complete vertically integrated product line. Prior to Australian Primary Hemp, Mr Hood had roles in agriculture, subsea engineering and digital software development.
Ms Pauline Therese Gately	Non-Executive Director, Non-Executive Chairman	Oct 2019	Ms Pauline Therese Gately Non-Executive Director, Non-Executive Chairman Ms Gately has experience across a range of portfolio of Board positions. Pauline brings a commercial focus to strategy and risk. She embraces dynamic business environments and has knowledge of navigating changing directional points. Her experience spans IPO through acquisitions and mergers. During her investment banking career, Pauline held senior positions with CitiBank, BNP International, Merrill Lynch, and Deutsche Bank. She served as a non-executive director and subsequently executive chairperson of Alliance Mineral Assets Limited (SGX: 40F) from 2011 through to December 2018. She is also member of Risk Committee.
Mr Cameron Petricevic	Non-Executive Director	Jun 2018	Mr Cameron Petricevic Non-Executive Director Mr Petricevic has spent over 15 years in the financial industry, with roles at AXA Asia Pacific Holdings (now AMP) and Acorn Capital. Cameron has investment banking experience, including valuations, mergers and acquisitions, and portfolio management. Cameron is a director of Kentgrove Equity Partners Pty Ltd and several private businesses. Cameron is Founder/Treasurer of Brimbank ToRCH, a Royal Children's Hospital auxiliary charity. He is member of the Risk Committee.
Dr Tracie Ramsdale	Non-Executive Director	May 2018	Dr Tracie Ramsdale Non-Executive Director Dr Ramsdale following a successful career as a Principal Investigator and Commercial Manager of the Centre for Drug Design and Development at the University of Queensland, Tracie co-founded Alchemia Limited, a drug discovery and development company and served as the company's CEO for almost 10 years. During this time, she was responsible for multiple financing transactions and licensing the company's technology to international pharmaceutical and manufacturing partners. Dr Ramsdale has served on a number of industry and government advisory groups and provided independent consulting advice to the biotechnology industry, academia and government. Tracie is a Fellow of the Australian Academy of Technological Sciences and Engineering, and a Member of the Australian Institute of Company Directors.
Ms Melanie Jaye Leydin	Chief Financial Officer, Company Secretary	Apr 2016	Ms Melanie Jaye Leydin Chief Financial Officer, Company Secretary Ms Leydin graduated from Swinburne University in 1997, became a Chartered Accountant in 1999 and since February 2000 has been the principal of LeydinFreyer. The practice provides outsourced company secretarial and accounting services to public and private companies specialising in ASX listed entities. Melanie has over 25 years experience in the accounting profession and has experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies and shareholder relations.
Dr Melvyn John Bridges	Non-Executive Director	Sep 2015	Dr Melvyn John Bridges Non-Executive Director Dr Bridges has over 35 years experience founding and building international lifescience, diagnostic and medical device companies and commercialising a range of Australian technology. He is in charge for commercial and M&A transactions and liquidity events, including listings on the ASX. He has founded and had develop medical device and diagnostic companies, including Pacific Diagnostics (acquired by Baxter), PanBio Ltd (acquired by Inverness Medical). He was a director of Tissue Therapies Ltd (March 2009 to December 2015), Benitec BioPharma Limited (October 2007 to June 2014) and Anatara Lifesciences Ltd (until May 2018). He serves as a member of the Risk Management Committee.
Mr David Lamm	Executive Chairman, Executive Director	Jul 2015	Mr David Lamm Executive Chairman, Executive Director Mr Lamm has over 16 years of experience in business and financial markets including roles at Credit Suisse, Bain & Company and the Alter Family Office. He is the founder and Managing Director of Kentgrove Capital. He is the Chairman of Investment Committee.
Peter Smith		N/A
Charles Mann		N/A
Timothy Hughes		N/A
Carlo Montagner		N/A
Susan Kelley		N/A
Darren Book		N/A
Nathan Drona		N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
22/10/20	Pauline Gately	Issued	334,000	$0.18	$60,120	Issue of options
22/10/20	Cameron Petricevic	Issued	334,000	$0.18	$60,120	Issue of options
21/10/20	James Hood	Issued	2,280,000	$0.18	$410,400	Issue of securities
18/11/19	Charles Mann	Buy	+249,020	$0.201	$50,043	On-market trade
14/11/19	Charles Mann	Buy	+657	$0.18	$118	On-market trade
11/11/19	Charles Mann	Buy	+4,494	$0.18	$809	On-market trade
02/10/19	Cameron Petricevic	Issued	1,216,904	$0.011	$13,386	Issue of securities
02/10/19	Cameron Petricevic	Issued	4,196,500	$0.011	$46,162	Issue of securities

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Pauline Gately	22/10/2020	50,000	N/A	334,000	N/A
Cameron Petricevic	22/10/2020	N/A	4,999,999	1,550,904	N/A
James Hood	21/10/2020	N/A	7,600,000	5,369,231	N/A
Neale Joseph	08/10/2020	N/A	33,896	N/A	N/A
Melanie Leydin	02/10/2019	0	125,000	N/A	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
CIA Mann Family Pty Ltd	8,543,671	12.25%
HSBC Custody Nominees (Australia) Limited	5,499,786	7.88%
James Robert Hood Pty Ltd	5,320,000	7.63%
TTOR Pty Ltd	4,999,999	7.17%
Mutual Trust Pty Ltd	3,250,000	4.66%
Crofton Park Development Pty Ltd	2,736,667	3.92%
Jasforce Pty Ltd	2,350,000	3.37%
CG Nominees (Australia) Pty Ltd	2,000,000	2.87%
Shomron Pty Ltd	1,971,338	2.83%
Sem Patterson Pty Ltd	1,540,000	2.21%
LD Fifty Ltd	1,250,000	1.79%
Cassa Trading Pty Ltd	1,227,435	1.76%
Brittany Pty Ltd	1,100,000	1.58%
Mr Ashley James Hardwick	1,100,000	1.58%
Peter Johnson & Kim Johnson	1,100,000	1.58%
NA Investments (Vic) No 2 Pty Ltd	1,100,000	1.58%
Stepheno Holdings Pty Ltd	971,022	1.39%
Citicorp Nominees Pty Limited	671,106	0.96%
Kent Street Capital No. 2 Pty Ltd	650,000	0.93%
Okulicz Pty Ltd	640,661	0.92%

Show All

Shareholder Distribution

Substantial Shareholders

Shareholders Buying

Shareholders Selling

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.11	30 June

APH Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.